Bernard H. Garil

Global High Income Fund, Inc. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve a high level of current income. As a secondary objective the fund seeks capital appreciation, to the extent consistent with its primary objective. Global High Income Fund was founded on February 23, 1993 and is headquartered in New York, NY.

Strategic Global Income Fund, Inc. is a closed end investment trust. The fund's primary investment objective is to achieve a high level of current income and secondary objective is to seek capital appreciation, to the extent consistent with its primary objective. The company was founded on February 3, 1992 and is headquartered in New York, NY.

Investment Grade Municipal Income Fund, Inc. is a closed end investment trust founded on August 6, 1992 and is headquartered in New York, NY

Insured Municipal Income Fund Inc., is a closed-end diversified management investment company. The Fund's investment objective is to achieve a high-level of current income that is exempt from federal income tax, consistent with the preservation of capital. Insured Municipal Income Fund Inc. , incorporated on February 18, 1993

Managed High Yield Fund Inc. is a diversified, closed-end management investment company. The Fund's investment objective is to seek high current income. Managed High Yield Fund was founded on April 24, 1998 and is headquartered in New York, NY.

Pacific Investment Management Co. LLC (PIMCO) is a SEC-registered investment advisor headquartered in Newport Beach, California. Founded in 1971, the firm is a subsidiary of Allianz Asset Management of America LP and their ultimate parent is Allianz SE (ETR: ALV), a German global insurance company. PIMCO provides discretionary investment management services to a global client base.

The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY.